#1 Clinical Trials Search in Europe

Crgd-Zw800-1

The drug cRGD-ZW800-1 is being investigated in several clinical trials for its potential to enhance cancer surgery through fluorescence-guided imaging. This innovative approach aims to improve the visualization of tumors and their margins during surgical procedures, potentially leading to more precise and complete tumor removal in various types of cancer, including oral, laryngeal, hypopharyngeal, pancreatic, and bile duct cancers.

Table of Contents

What is CRGD-ZW800-1?

CRGD-ZW800-1 is a new drug being studied to help surgeons see cancer more clearly during operations[1]. It’s not a treatment that kills cancer cells, but rather a tool to make tumors “light up” during surgery. This could help doctors remove cancer more accurately.

How Does It Work?

CRGD-ZW800-1 is what’s called a “targeted near-infrared fluorophore.” Let’s break that down:

  • Targeted: It’s designed to attach to specific things in the body.
  • Near-infrared: It produces light that’s almost, but not quite, visible to the human eye.
  • Fluorophore: A substance that glows when exposed to light.

This drug attaches to proteins called integrins, which are often found in higher amounts on cancer cells and in the blood vessels that feed tumors[2]. When the surgeon shines a special light on the area during surgery, the CRGD-ZW800-1 glows, helping to show where the cancer is.

Types of Cancer Being Studied

Researchers are currently testing CRGD-ZW800-1 in several types of cancer:

  • Oral cancer: Cancer in the mouth[1]
  • Laryngeal cancer: Cancer of the voice box[2]
  • Hypopharyngeal cancer: Cancer in the lower part of the throat[2]
  • Pancreatic cancer: Cancer of the pancreas[3]
  • Cholangiocarcinoma: Cancer of the bile ducts[3]

Current Clinical Trials

There are several ongoing clinical trials testing CRGD-ZW800-1:

  1. A study for oral cancer patients undergoing surgery[1]
  2. A trial for patients with laryngeal or hypopharyngeal cancer having their voice box removed[2]
  3. A study for patients with pancreatic cancer or bile duct cancer[3]

These trials are testing different doses of the drug and looking at how well it helps surgeons see the cancer during operations.

Potential Benefits

If CRGD-ZW800-1 works as hoped, it could have several benefits for cancer patients:

  • Help surgeons remove all of the cancer more accurately
  • Reduce the chance of leaving cancer behind after surgery
  • Help identify cancer that has spread to nearby lymph nodes
  • Potentially improve survival rates for cancer patients

How is CRGD-ZW800-1 Administered?

CRGD-ZW800-1 is given as a single injection into a vein (intravenously). The timing of the injection varies in different studies:

  • Some patients receive it 2-4 hours before surgery[3]
  • Others receive it 14-24 hours before surgery[3]
  • In some studies, it’s given 16-20 hours before surgery[1]

The exact timing and dose are still being studied to find out what works best.

Safety and Side Effects

As CRGD-ZW800-1 is still in clinical trials, researchers are carefully monitoring for any side effects or safety concerns[3]. So far, no major safety issues have been reported in the available information. However, as with any new medical treatment, patients should be aware that there may be unknown risks.

It’s important to note that this drug is not a cancer treatment itself – it’s a tool to help make surgery more effective. Patients considering participating in a clinical trial for CRGD-ZW800-1 should discuss the potential risks and benefits with their healthcare team.

Aspect Details
Drug Name cRGD-ZW800-1
Type Targeted near-infrared fluorophore
Mechanism Binds to integrins overexpressed in cancer cells and tumor-associated blood vessels
Administration Single intravenous bolus injection before surgery
Cancer Types Studied Oral, laryngeal, hypopharyngeal, pancreatic, and bile duct cancers
Primary Objectives Improve tumor visualization, achieve clear resection margins, detect lymph node involvement
Potential Benefits More complete tumor removal, improved surgical outcomes, potential increase in survival rates
Current Stage Phase I/II clinical trials for dose optimization and feasibility assessment
Key Outcome Measures Tumor-to-background ratio, rate of clear resection margins, detection of positive lymph nodes

FAQ

  • What is cRGD-ZW800-1 and how does it work? cRGD-ZW800-1 is a targeted near-infrared fluorophore that binds to specific proteins (integrins) often overexpressed in cancer cells and tumor-associated blood vessels. When injected into the patient, it accumulates in tumor tissue and emits light in the near-infrared spectrum, allowing surgeons to visualize cancer cells during surgery using special imaging systems.
  • What types of cancer are being studied with cRGD-ZW800-1? Current clinical trials are investigating the use of cRGD-ZW800-1 in oral cancer, laryngeal and hypopharyngeal cancers, pancreatic cancer, and bile duct cancer (cholangiocarcinoma).
  • How is cRGD-ZW800-1 administered to patients? cRGD-ZW800-1 is administered as a single intravenous bolus injection, typically within a few hours to a day before the surgical procedure, depending on the specific trial protocol.
  • What are the potential benefits of using cRGD-ZW800-1 in cancer surgery? The use of cRGD-ZW800-1 may help surgeons better visualize tumor boundaries, potentially leading to more complete tumor removal, reduced positive margins, and improved detection of involved lymph nodes or metastases. This could potentially improve patient outcomes and overall survival rates.
  • Are there any known side effects or risks associated with cRGD-ZW800-1? While the trials are ongoing and full safety data is not yet available, the studies are monitoring for any adverse events or toxicity related to cRGD-ZW800-1 administration. Safety and tolerability are important aspects being evaluated in these clinical trials.

Ongoing Clinical Trials on Crgd-Zw800-1

  • Study on Fluorescence-Guided Surgery Using cRGD-ZW800-1 for Patients with Laryngeal and Hypopharyngeal Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Improving Oral Cancer Surgery Using cRGD-ZW800-1 Fluorescent Imaging for Patients with Oral Cancer

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Fluorescence Imaging (FLI): A technique that uses special dyes or markers that emit light to visualize specific tissues or structures during surgery.
  • Tumor-to-background ratio (TBR): A measure of how well the tumor can be distinguished from surrounding normal tissue using fluorescence imaging. A higher TBR indicates better visibility of the tumor.
  • Resection margins: The edges of tissue removed during cancer surgery. Clear or negative margins mean no cancer cells are found at the edges, while positive margins indicate cancer cells are present at the edge of the removed tissue.
  • Neoadjuvant therapy: Treatment, such as chemotherapy or radiation, given before the main treatment (usually surgery) to shrink the tumor and make it easier to remove.
  • Integrins: Proteins on cell surfaces that cRGD-ZW800-1 binds to, which are often overexpressed in cancer cells and involved in the formation of new blood vessels in tumors.
  • Near-infrared (NIR) spectrum: A range of light wavelengths just beyond visible light that can penetrate deeper into tissue, making it useful for medical imaging.
  • R0 resection: A surgical outcome where all visible and microscopic tumor tissue has been removed, with no cancer cells found at the edges of the removed tissue.
  • Cholangiocarcinoma: A type of cancer that forms in the bile ducts, which are tubes that connect the liver to the small intestine.

References